Acasti Pharma | ACST - Cash And Equivalent


Acasti Pharma reported $16.86M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 16.86M 3.14M Sep/2025
Addus HomeCare USD 101.92M 10.74M Sep/2025
Amarin USD 122.8M 25.08M Sep/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Knight Therapeutics CAD 77.82M 34.34M Jun/2025
Option Care Health USD 309.82M 111M Sep/2025
Organigram Holdings CAD 28.2M 7.68M Sep/2025
Tilray USD 264.83M 43.16M Jun/2025